Please use this identifier to cite or link to this item:
Title: Current State of Neoadjuvant Radiotherapy for Rectal Cancer.
Austin Authors: Ng, Sweet Ping ;Ngan, Samuel Y;Leong, Trevor
Affiliation: Department of Surgery, The University of Melbourne, Melbourne, Australia
Radiation Oncology
School of Molecular Sciences, La Trobe University, Melbourne, Australia
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
Olivia Newton-John Cancer Wellness and Research Centre
Issue Date: 2022 2021-11-04
Publication information: Clinical Colorectal Cancer 2022; 21(1): 63-70
Abstract: Colorectal cancer is the third most commonly diagnosed cancer, with rectal cancer accounting for 30% of cases. The current standard of care curative treatment for locally advanced rectal cancer is (chemo)radiotherapy followed by surgery and adjuvant chemotherapy. Although neoadjuvant radiotherapy has reduced the risk of local recurrence to less than 10%, the risk of distant metastasis remained high at 30% affecting patient survival. In addition, there is a recognition that there is heterogeneity in tumor biology and treatment response with good responders potentially suitable for treatment de-escalation. Therefore, new treatment sequencing and regimens were investigated. Here, we reviewed the evidence for current neoadjuvant treatment options in patients with locally advanced rectal adenocarcinoma, and highlight the new challenges in this new treatment landscape.
DOI: 10.1016/j.clcc.2021.10.008
Journal: Clinical Colorectal Cancer
PubMed URL: 34852972
Type: Journal Article
Subjects: Biomarker
Locally advanced
Short course
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 6, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.